TGFBR2 and cancer: Taken together, these data demonstrate that the therapeutic efficacy of TGFβR2 blockade in TGFβR2‐mutant PDA is a result of the inhibition of the CAF TGFβ‐IL‐6 paracrine signal that drives cancer cell proliferation and inhibits NK cell activity (Appendix Fig S8).